Back to results
US 2020/0399698 A1Published application
Methods of determining response to tnf alpha blockers
AssigneesGenefron Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem
InventorYoav SMITH
Life of this patent
Estimating the term…
Abstract
Methods and kits for predicting the response of a subject to an anti-TNFα therapy, in high accuracy, are provided.
Claims20
A method for determining and treating a subject suitable to receive anti-TNFα therapy, the method comprising the step of:
- a. determining an expression level sum of three genes in a biological sample obtained from the subject, wherein said three genes are
- i. MX1
- ii. at least one gene selected from IFI6 and OAS3, and
- iii. at least one gene selected from the group consisting of:
- IFI6, OAS1, OAS3, DDX58, RSAD2, IFIT1, IFIT3, IFI44, IFI44L, IFITM3, and HERC5;
- and
- b. generating a diagnosis regarding suitability to receive anti-TNFα therapy wherein:
- an expression level sum above a predetermined threshold, is indicative of the subject being suitable to receive anti-TNFα therapy, and
- an expression level sum below a predetermined threshold, is indicative of the subject being unsuitable to receive anti-TNFα therapy,
- c. treating said subject being suitable to receive anti-TNFα therapy, with anti-TNFα therapy;
- thereby treating a subject suitable to receive anti-TNFα therapy.
8 more elements
A kit comprising reagents adapted to specifically determine the expression level of MX1, and at least one of IFI6, and OAS3.
Dependencies are inferred from the claim text.